Neuropeptide Y2 receptors as drug targets for the central regulation of body weight

Current Opinion in Investigational Drugs

Volumn 6, Issue 10, 2005, Pages 1002-1011

  Félétou, Michel ^a   Levens, Nigel R ^b  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b BIOVITRUM AB   (Sweden)

Author keywords

Cardiovascular; Gastrointestinal; Neuropeptide Y; Neuropeptide Y receptor; PYY3 36

Indexed keywords

4 AMINOBUTYRIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANOREXIGENIC AGENT; HYPOPHYSIS HORMONE; MELANOCORTIN; MESSENGER RNA; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR STIMULATING AGENT; PEPTIDE YY; PROOPIOMELANOCORTIN; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; LIGAND; NEUROPEPTIDE Y RECEPTOR;

ANXIETY DISORDER; BODY WEIGHT; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; FOOD INTAKE; GASTROINTESTINAL DISEASE; GENETIC CODE; HORMONE RELEASE; HYPOTHALAMUS; METABOLIC PARAMETERS; MOLECULAR MECHANICS; NEUROTRANSMISSION; NONHUMAN; OBESITY; RECEPTOR AFFINITY; REVIEW; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; BRAIN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; OBESITY; RECEPTORS, NEUROPEPTIDE Y;

EID: 27544443953     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Zagorsky JL: Health and wealth. The late-20th century obesity epidemic in the U.S. Econ Hum Biol (2005) 3(2):296-313.
2. Douketis JD, Sharma AM: Obesity and cardiovascular disease: Pathogenic mechanisms and potential benefits of weight reduction. Semin Vasc Med (2005) 5(1):25-33.
3. Sheehan MT: Current therapeutic options in type 2 diabetes mellitus: A practical approach. Clin Med Res (2003) 1(3):189-200.
4. Honthaas Ch, Ritz P: Energy expenditure: Method employed. Ann Endocrinol (2002) 63(6 Pt 2):S30-S37.
5. Ioannides-Demos LL, Proietto J, McNeil JJ: Pharmacotherapy for obesity. Drugs (2005) 65(10):1391-1418.
6. Chaput JP, Berube-Parent S, Tremblay A: Obesity and cardiovascular physiology: Impact of some pharmacological agents. Curr Vasc Phannacol (2005) 3(2):185-193.
7. King PJ: The hypothalamus and obesity. Curr Drug Targets (2005) 6(2):225-240.
8. Stanley BG, Leibowitz SF: Neuropeptide Y: Stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci (1984) 35(26):2635-2642.
9. Levine AS, Morley JE: Neuropeptide Y: A potent inducer of consummatory behavior in rats. Peptides (1984) 5(6):1025-1029.
10. Clark JT, Kalra PS, Crowley WR, Kalra SP: Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology (1984) 115(1):427-429.
11. Wahlestedt C, Skagerberg G, Ekman R, Heilig M, Sundler F, Hakanson R: Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat. Brain Res (1987) 417(1):33-38.
12. Fekete C, Kelly J, Mihaly E, Sarkar S, Rand WM, Legradi G, Emerson CH, Lechan RM: Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis. Endocrinology (2001) 142(6):2606-2613.
13. Currie PJ, Coscina DV: Dissociated feeding and hypothermic effects of neuropeptide Y in the paraventricular and perifornical hypothalamus. Peptides (1995) 16(4):599-604.
14. Billington CJ, Briggs JE, Harker S, Grace M, Levine AS: Neuropeptide Y in hypothalamic paraventricular nucleus: A center coordinating energy metabolism. Am J Physiol (1994) 266(6 Pt2):R1765-R1770.
15. van Dijk G, Bottone AE, Strubbe JH, Steffens AB: Hormonal and metabolic effects of paraventricular hypothalamic administration of neuropeptide Y during rest and feeding. Brain Res (1994) 660(1):96-103.
16. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML: Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol (2001) 185(1-2):195-204.
17. Kaga T, Inui A, Okita M, Asakawa A, Ueno N, Kasuga M, Fujimiya M, Nishimura N, Dobashi R, Morimoto Y, Liu IM et al: Modest overexpression of neuropeptide Y in the brain leads to obesity after high-sucrose feeding. Diabetes (2001) 50(5):1206-1210.
18. Akabayashi A, Levin N, Paez X, Alexander JT, Leibowitz SF: Hypothalamic neuropeptide Y and its gene expression: Relation to light/dark cycle and circulating corticosterone. Mol Cell Neurosci (1994) 5(3):210-218.
19. Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS: Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA (1991) 88(23):10931-10935.
20. Sahu A, Kalra PS, Kalra SP: Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides (1988) 9(1):83-86.
21. Malabu UH, Kilpatrick A, Ware M, Vernon RG, Williams G: Increased neuropeptide Y concentrations in specific hypothalamic regions of lactating rats: Possible relationship to hyperphagia and adaptive changes in energy balance. Peptides (1994) 15(1):83-87.
22. Abe M, Saito M, Ikeda H, Shimazu T: Increased neuropeptide Y content in the arcuato-paraventricular hypothalamic neuronal system in both insulin-dependent and non-insulin-dependent diabetic rats. Brain Res (1991) 539(2):223-227.
23. Holliday ND, Michel MC, Cox HM: NPY receptor subtypes and their signal transduction. In: Neuropeptide Y and Related Peptides. Handbook of Experimental Pharmacology. MC Michel (Ed), Springer-Verlag, Berlin, Germany (2004) 162:45-74.
24. Larhammar D, Fredriksson R, Larson ET, Salaneck E: Phylogeny of NPY-family peptides and their receptors. In: Neuropeptide Y and Related Peptides. Handbook of Experimental Pharmacology. Michel MC (Ed), Springer-Verlag, Berlin, Germany (2004) 162:75-101.
25. 3 receptor? Regul Pept (1998) 75-76:71-78.
26. Weinberg DH, Sirinathsinghji DJ, Tan CP, Shiao LL, Morin N, Rigby MR, Heavens RH, Rapoport DR, Bayne ML, Cascieri MA, Strader CD et al: Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem (1996) 271(28):16435-16438.
27. Burkhoff A, Linemeyer DL, Salon JA: Distribution of a novel hypothalamic neuropeptide Y receptor gene and it's absence in rat. Brain Res Mol Brain Res (1998) 53(1-2):311-316.
28. Fetissov SO, Kopp J, Holdelt T: Distribution of NPY receptors in the hypothalamus. Neuropeptides (2004) 38(4):175-188.
29. 1 receptor agonists with orexigenic activity in vivo. Mol Pharmacol (2001) 60(3):534-540.
30. 5-receptor preferring ligand with strong stimulatory effect on food intake. Regul Pept (2000) 87(1-3):47-58.
31. 1 receptor-deficient mice. Proc Natl Acad Sci USA (1998) 95(26):15659-15664.
32. 5 neuropeptide Y receptor in feeding and obesity. Nat Med (1998) 4(6):718-721.
33. 1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept (1995) 59(2):201-205.
34. 5 receptor antisense oligodeoxynucleotides. Diabetes (1997) 46(11):1792-1798.
35. Dryden S, Pickavance L, Tidd D, Williams G: The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus. J Endocrinol (1998) 157(1):169-175.
36. 1 receptor. Neurosci Biobehav Rev (2005) 29(1):113-123.
37. 5 receptors in anxiety and sedation. J Neurosci Res (2004) 77(5):723-729.
38. 5 receptor. Int J Obesity Relat Metab Disord (2004) 28(4):628-639.
39. 5 receptor does not have a major effect on feeding in rats. Diabetes (2002) 51(8):2441-2449.
40. 5r expression. Endocrinology (2004) 145(1):304-310.
41. 2 receptor antagonist. Br J Pharmacol (2000) 129(6):1075-1088.
42. 2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology (1997) 66(6):393-408.
43. Parker RM, Herzog H: Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci (1999) 11(4):1431-1448.
44. 2 receptor antagonist BIIE0246 on presynaptic inhibition by neuropeptide Y in rat hippocampal slices. Eur J Pharmacol (2000) 404(1-2):133-136.
45. 2 receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol (2000) 396(1):R1-R3.
46. Trivedi PG, Yu H, Trumbauer M, Chen H, Van der Ploeg LH, Guan X: Differential regulation of neuropeptide Y receptors in the brains of NPY knock-out mice. Peptides (2001) 22(3):395-403.
47. Chen G, van den Pol AN: Multiple NPY receptors coexist in pre- and postsynaptic, sites: Inhibition of GABA release in isolated self-innervating SCN neurons. J Neurosci (1996) 16(23):7711-7724.
48. 2 receptor messenger RNA in the human post mortem brain. Neuroscience (1998) 86(1):167-178.
49. 1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. J Chem Neuroanat (2000) 20(3-4):327-337.
50. 2 receptor subtypes in human and rat brain. Brain Res (1993) 631(1):27-38.
51. 5 receptor? Regul Pept (1998) 75-76:355-361.
52. 4 subtypes. Regul Pept (1998) 75-76:363-371.
53. 3-36 physiologically inhibits food intake. Nature (2002) 418(6898):650-654.
54. 5 receptors. Obes Res (2005) 13(1):36-47.
55. Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD: Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: Evidence of a cellular basis for the adipostat. Neuron (1999) 24(1):155-163.
56. Roseberry AG, Liu H, Jackson AC, Cai X, Friedman JM: Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice. Neuron (2004) 41(5):711-722.
57. 2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci USA (2002) 99(13):8938-8943.
58. Druce MR, Small CJ, Bloom SR: Minireview: Gut peptides regulating satiety. Endocrinology (2004) 145(6):2660-2665.
59. 2 receptor. Nat Med (1999) 5(10):1188-1193.
60. 2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice, Diabetes (2002) 51(12):3420-3427.
61. 2 receptor antagonism in the rat: Effects on feeding behaviour. J Neuroendocrinol (2005) 17(7):452-457.
62. 3-36 an food intake. Brain Res (2005) 1043(1-2):139-144.
63. 2. Ann NY Acad Sci (11990) 611:7-26.
64. 2-receptors. Naunyn Schmiedebergs Arch Pharmacol (2004) 369(5):455-461.
65. 2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. Eur J Pharmacol (1997) 336(2-3):257-265.
66. 4 receptors in smooth muscle coupled to distinct signaling pathways. J Pharmacol Exp Ther (2004) 311(3):1154-1162.
67. 2-receptor-mediated cardiovascular effects in the anesthetized guinea pig, rat, and rabbit. J Cardiovasc Pharmacol (2000) 36(4):451-458.
68. 2 receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept (2002) 103(2-3):105-111.
69. Smith-White MA, Iismaa TP, Potter EK: Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse. Br J Pharmacol (2003) 140(1):170-178.
70. 2 receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept (2002) 103(2-3):105-111.
71. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS: Neuropeptide Y: A novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res (1998) 83(2):187-195.
72. Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander AC, Hassani H, Hallberg B, Nordlander M, Cao Y: Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci USA (2003) 100(10):6033-6038.
73. Lee EW, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P, Sangkharat A, Ji H, Li L, Michalkiewicz T, Ljubisavljevic M et al: Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest (2003) 111(12):1853-1862.
74. 2 antagonism in mouse and human colonic tissues. Br J Pharmacol (2003) 139(4):863-871.
75. Browning KN, Lees GM: Inhibitory effects of NPY on ganglionic transmission in myenteric neurones of the guinea-pig descending colon. Neurogastroenterol Motil (2000) 12(1):33-41.
76. 2 receptor activation. J Neuroimmunol (2004) 155(1-2):1-12.
77. 5 receptors. Regul Pept (2005) 124(1-3):163-72.
78. Ekblad E, Sundler F: Distribution of pancreatic polypeptide and peptide YY. Peptides (2002) 23(2):251-261.
79. Medeiros MD, Turner AJ: Processing and metabolism of peptide-YY: Pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology (1994) 134(5):2088-2094.
80. Batterham RL, Bloom SR: The gut hormone peptide YY regulates appetite. Ann NY Acad Sci (2003) 994:162-168.
81. Lin HC, Taylor IL: Release of peptide YY by fat in the proximal but not distal gut depends on an atropine-sensitive cholinergic pathway. Regul Pept (2004) 117(1):73-76.
82. Chey WY, Chang T: Neural hormonal regulation of exocrine pancreatic secretion. Pancreatology (2001) 1(4):320-335.
83. Clave P, Lluis F, Thompson JC, Greeley GH Jr: Peptide YY inhibits gastric acid secretion stimulated by the autonomic nervous system. Biol Signals (1992) 1(1):40-45.
84. Lin HC, Neevel C, Chen JH: Slowing intestinal transit by PYY depends on serotonergic and opioid pathways. Am J Physiol - Gastrointest Liver Physiol (2004) 286(4):G558-G563.
85. Stanley BG, Daniel DR, Chin AS, Leibowitz SF: Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides (1985) 6(6):1205-1211.
86. 2 receptor antagonism in the rat: Effects on feeding behaviour. J Neuroendocrinol (2005) 17(7):452-457.
87. 2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology (1997) 66(6):393-408.
88. 3-36 inhibits food intake in mice through a metanocortin-4 receptor-independent mechanism. Endocrinology (2004) 145(6):2585-2590.
89. 3-36. Proc Natl Acad Sci USA (2004) 101(13):4695-4700.
90. 3-36 produces conditioned taste aversion in mice. Cell Metab (2005) 1(3):159-168.
91. 3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res (2005) 1044(1):127-131.
92. 3-36-induced feeding reduction in rats. Endocrinology (2005) 146(5):2369-2375.
93. 3-36 decrease food intake in rodents? Nature (2004) 430(6996):1-2.
94. 3-36 potently inhibits food intake in rats. Endocrinology (2005) 146(2):879-888.
95. 3-36 in the treatment of obesity. Expert Opin Invest Drugs (2005) 14(5):647-653.
96. 3-36 inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol - Regulat Integrat Comparat Physiol (2005) 288(2):R384-R388.
97. 2 receptor genes in relation to human obesity and obesity-related traits. Diabetes (2004) 53(9):2461-2466.
98. 72 allele of the peptide YY and increased risk of type 2 diabetes. Diabetes (2005) 54(7):2261-2265.
99. 2 receptor genes are associated with severe obesity in Pima Indian men. Diabetes (2005) 54(5):1598-1602.
100. 2 receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci (2004) 22(3):159-166.
101. 2 receptor knockout mice. Behav Brain Res (2003) 141(2):251-255.
102. 2 receptors on neuropeptide Y-induced sensitization to sedation. J Neurochem (2001) 78(6):1201-1207.
103. 2 receptors regulate bone formation. J Clin Invest (2002) 109(7):915-921.
104. Small CJ, Morgan DG, Meeran K, Heath MM, Gunn I, Edwards CM, Gardiner J, Taylor GM, Hurley JD, Rossi M, Goldstone AP et al: Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release. Proc Natl Acad Sci USA (1997) 94(21):11686-11691.
105. Barker-Gibb ML, Scott CJ, Boublik JH, Clarke IJ: The role of neuropeptide Y (NPY) in the control of LH secretion in the ewe with respect to season, NPY receptor subtype and the site of action in the hypothalamus. J Endocrinol (1995) 147(3):565-579.
106. 2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann Med (2004) 36(3):232-240.
107. 5 receptor gene in the human brain: An in situ hybridization study. Brain Res Mol Brain Res (1998) 61(1-2):100-107.
108. 3-36 in the mouse. J Pharmacol Exp Ther (2003) 306(3):948-953.
109. 5 receptor agonist with dramatic effects on food intake. Peptides (2000) 21(3):393-399.
110. 5 receptor gene in the human brain: An in situ hybridization study. Brain Res Mol Brain Res (1998) 61(1-2):100-107.
111. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO et al: A receptor subtype involved in neuropeptide-Y-induced food intake. Nature (1996) 382(6587):168-171.
112. Zukowska Z, Grant DS, Lee EW: Neuropeptide Y: A novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med (2003) 13(2):86-92.
113. 5 receptors. Proc Natl Acad Sci USA (2000) 97(4):1595-1600.
114. 2 receptor binding in the nucleus tractus solitarius. Brain Res (1995) 684(2):159-164.
115. Wager-Page SA, Raizada E, Veale WL, Davison JS: Spinal modulation of duodenal and colonic motility and arterial pressure by neuropeptide Y, neuropeptide Y fragment 13-36, peptide YY, and pancreatic polypeptide in rats: Involvement of the cholinergic nervous system. Can J Physiol Pharmacol (1993) 71(2):112-119.
116. Adrian TE, Sagor GR, Savage AP, Bacarese-Hamilton AJ, Hall GM, Bloom SR: Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man. J Clin Endocrinol Metab (1986) 63(4):803-807.
117. 3-36 reveals divergent cardiovascular effects of endogenous NPY in rats on different dietary regimens. Am J Physiol - Regulat Integrat Comparat Physiol (2004) 286(1):R138-R142.